Innovent Biologics, Inc. (HKG:1801)
94.35
-3.85 (-3.92%)
Sep 10, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 8,754 employees as of June 30, 2026. The number of employees increased by 1,252 or 16.69% since the number was reported on December 31, 2025.
Employees
8,754
Change
1,252
Growth
16.69%
Revenue / Employee
2.07M HKD
Profits / Employee
162.53K HKD
Market Cap
164.26B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 8,754 | 1,252 | 16.69% |
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| BeOne Medicines AG | 12,000 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
Innovent Biologics News
- 16 days ago - Innovent Announces 2026 Interim Results And Strategic Vision Toward 2030 - Nasdaq
- 16 days ago - Innovent Biologics Earnings release: H1 2026 - Filings
- 16 days ago - Innovent Biologics Slides: H1 2026 - Filings
- 4 weeks ago - Innovent, Daiichi Sankyo Ink China Deal For VANFLYTA Commercialization - Nasdaq
- 4 weeks ago - Innovent Biologics Secures China Commercialization Rights For Vanflyta In Deal With Daiichi Sankyo - Nasdaq
- 4 weeks ago - Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China - PRNewsWire
- 1 month ago - Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion - Reuters
- 1 month ago - Spero Therapeutics, Innovent Biologics enter license agreement for SP001 - TheFly